ライフサイエンスコーパス: PBSCT

1 PBSCT for POEMS syndrome is effective therapy but may al

2 PBSCT patients also received identical mobilization with

3 PBSCT patients had significantly faster engraftment of a

4 PBSCT produced a complete response in 2 patients, a part

5 FLC measurements both before and after PBSCT are important predictors of patient outcome.

6 acute and chronic GVHD are more common after PBSCT than BMT, and this may be associated with lower ra

7 Twenty-eight to 80 days after PBSCT, patients were randomized to IL-2 versus observati

8 by leukapheresis in all patients even after PBSCT.

9 at DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses.

10 he incidence of acute and chronic GVHD after PBSCT and BMT reported as of June, 2000.

11 hese results suggest that chronic GVHD after PBSCT may be more protracted and less responsive to curr

12 inical characteristics of chronic GVHD after PBSCT might be distinct from those that occur after BMT.

13 oled relative risk (RR) for acute GVHD after PBSCT was 1.16 (95% confidence interval [CI], 1.04 to 1.

14 The pooled RR for chronic GVHD after PBSCT was 1.53 (95% CI, 1.25 to 1.88; P <.001) when comp

15 ded to control chronic GVHD was higher after PBSCT than after BMT (P =.03), and the duration of gluco

16 Normalization of FLC level after PBSCT predicted for both organ response and complete hem

17 of glucocorticoid treatment was longer after PBSCT compared to BMT (P =.03).

18 ards a decrease in the rate of relapse after PBSCT (RR = 0.81; 95% CI, 0.62 to 1.05).

19 T-cell repertoire in patients following allo-PBSCT.

20 following unmanipulated matched sibling allo-PBSCT and demonstrates that HLA class I tetramers comple

21 pulate the periphery of matched sibling allo-PBSCT patients.

22 pheral blood stem cell transplantation (allo-PBSCT) is a commonly used therapy in which T-cell survei

23 nthly intervals following unmanipulated allo-PBSCT demonstrated that the frequency of EBV-specific T

24 We propose that mixed allogeneic PBSCT for the interruption of the autoimmune process can

25 a illustrate that G-CSF-mobilized allogeneic PBSCT separate GVL from GVHD by preserving perforin-depe

26 and were subsequently treated with HDCT and PBSCT.

27 etoposide, total body irradiation (TBI), and PBSCT.

28 s that cyclophosphamide, etoposide, TBI, and PBSCT can be administered to patients with relapsed/refr

29 SCT) in patients with other PCDs, autologous PBSCT may be an attractive treatment option for this syn

30 for 3 consecutive days, and each followed by PBSCT.

31 tion studies that eventually led to clinical PBSCT.

32 For PBSCT and control groups, respectively, the 1-, 2-, and

33 Event-free survival was 37% for PBSCT and 37% for ABMT.

34 The complete response rate was 72% for PBSCT and 54% for ABMT.

35 However, overall survival for PBSCT was 61% compared with 43% for ABMT.

36 mediating GVL effects after G-CSF-mobilized PBSCT.

37 Assessment of the overall benefits of PBSCT compared to BMT will require continued long-term f

38 er modulates acute GVHD in a murine model of PBSCT.

39 Clinical trials comparing the outcome of PBSCT with BM transplantation, registry data analyses, a

40 nt the strongest data supporting the role of PBSCT in selected patients with AL.

41 ant day 100 was 2% on the ABMT arm and 6% on PBSCT arm.

42 psed metastatic GCT are curable by HDCT plus PBSCT even when used in third-line or later therapy.

43 MM patients received PBSCT to eradicate the majority of the disease.

44 stimulating factor (G-CSF) administration to PBSCT recipients, both with and without donor G-CSF pret

45 aggressive NHL receiving HSCT randomized to PBSCT demonstrated improved neutrophil engraftment and p

46 iving peripheral blood stem cell transplant (PBSCT) had significantly better survival than bone marro

47 peripheral-blood stem-cell transplantation (PBSCT) (n = 47).

48 peripheral-blood stem-cell transplantation (PBSCT) at Indiana University between 2004 and 2014.

49 peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations.

50 peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates an

51 peripheral blood stem cell transplantation (PBSCT) in patients with other PCDs, autologous PBSCT may

52 peripheral blood stem cell transplantation (PBSCT) is increasingly used instead of bone marrow trans

53 Peripheral blood stem cell transplantation (PBSCT) is the most common transplantation procedure perf

54 geneic peripheral stem cell transplantation (PBSCT) reduces the severity of acute GVHD in murine mode

55 peripheral blood stem cell transplantation (PBSCT) to bone marrow transplantation (BMT) from HLA-mat

56 peripheral-blood stem-cell transplantation (PBSCT) when compared with bone marrow transplantation (B

57 peripheral blood stem cell transplantation (PBSCT), but the selection process makes the apparent ben

58 after autologous stem-cell transplantation (PBSCT), patients with previously treated NHL were treate

59 peripheral blood stem cell transplantation (PBSCT).

60 Mixed PBSC transplantation (PBSCT) prevented the production of anti-DNA antibodies a

61 In 98 patients with AL undergoing PBSCT, serum cardiac biomarkers were measured (cTnT, 98

62 tool for staging patients with AL undergoing PBSCT.

63 patients with POEMS syndrome have undergone PBSCT at Mayo.